SCHEMBL320675

SCHEMBL320675

N#Cc1cc(S(=O)(=O)Cl)ccc1Br

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.38
ALDH1A1 P00352 2/20 0.34
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CA2 P00918 4/20 0.34
CA1 P00915 3/20 0.34
CA9 Q16790 3/20 0.34
CA12 O43570 2/20 0.34
EPAS1 Q99814 3/20 0.33
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
RRM1 P23921 1/20 0.33
RRM2B Q7LG56 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
SLC22A12 Q96S37 1/20 0.33
TRPV4 Q9HBA0 1/20 0.33
CA7 P43166 2/20 0.32
CA4 P22748 1/20 0.32
CA6 P23280 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31591563 1.00 GRM4 (0.38) GRM4ALDH1A1HSD17B10TDP1CA2
SCHEMBL1396710 0.85 CA2 (0.36) ALDH1A1HSD17B10TDP1CA2CA1
SCHEMBL1941288 0.82 EPAS1 (0.41) ALDH1A1HSD17B10TDP1EPAS1MEN1
SCHEMBL1939729 0.79 VCAM1 (0.51) GRM4ALDH1A1EPAS1MEN1KMT2A
SCHEMBL15794073 0.79 GAA (0.39) GRM4ALDH1A1CHRM2CHRM1RRM1
SCHEMBL25366711 0.78 TSHR (0.41) ALDH1A1HSD17B10TDP1EPAS1MEN1
SCHEMBL20870724 0.78 XDH (0.40) ALDH1A1HSD17B10TDP1CA2CA1
SCHEMBL319459 0.78 ACLY (0.47) GRM4EPAS1SLC22A12TRPV4VEGFA
SCHEMBL29814208 0.78 XDH (0.40) ALDH1A1HSD17B10TDP1CA2CA1
SCHEMBL30540035 0.78 TSHR (0.41) ALDH1A1HSD17B10TDP1EPAS1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3655405-B1 CHEMICAL COMPOUNDS ANTABIO SAS (FR) 2023-06-07 EP disclosed
EP-3655405-B1 CHEMICAL COMPOUNDS ANTABIO SAS (FR) 2023-06-07 EP disclosed
CN-115745910-A Chemical compound 安塔比奥公司 2023-03-07 CN disclosed
CN-110446708-B Chemical compound 安塔比奥公司 2022-12-02 CN disclosed
US-20220315546-A1 CHEMICAL COMPOUNDS ANTABIO SAS (FR) 2022-10-06 US disclosed
US-11299467-B2 Chemical compounds ANTABIO SAS (FR) 2022-04-12 US disclosed
US-10889555-B2 Sulfonamide compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 US disclosed
US-20200405697-A1 Antitumor Agent TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-31 US disclosed
US-20200399235-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-24 US disclosed
US-20200339526-A1 CHEMICAL COMPOUNDS ANTABIO SAS (FR) 2020-10-29 US disclosed
US-9096558-B2 N-sulfonylbenzamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
US-9096558-B2 N-sulfonylbenzamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
US-9096558-B2 N-sulfonylbenzamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
EP-2590957-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-12 EP disclosed
EP-2590957-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-12 EP disclosed
EP-2590957-A2 CHEMICAL COMPOUNDS Pfizer Limited (GB) 2013-05-15 EP disclosed
US-20130109696-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
US-20130109696-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
US-20130109696-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
WO-2012004714-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315546-A1 CHEMICAL COMPOUNDS MRPL21, MLX, TXN GRM4 2788/4885ALDH1A1 1565/4885HSD17B10 3379/4885
US-20200399235-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 GRM4 4199/4885ALDH1A1 1103/4885HSD17B10 651/4885
US-11299467-B2 Chemical compounds MRPL21, MLX, CFTR GRM4 2945/4885ALDH1A1 1225/4885HSD17B10 3240/4885
US-20130109696-A1 Chemical Compounds SCN1A, SCN7A, SCN1B GRM4 2507/4885ALDH1A1 1451/4885HSD17B10 2972/4885
US-10889555-B2 Sulfonamide compound or salt thereof RNASEH1, SNRPA1, RRM2 GRM4 4199/4885ALDH1A1 1103/4885HSD17B10 651/4885
US-20200339526-A1 CHEMICAL COMPOUNDS MRPL21, MLX, CFTR GRM4 2945/4885ALDH1A1 1225/4885HSD17B10 3240/4885
US-20200405697-A1 Antitumor Agent HNRNPR, RRM2, RRM2B GRM4 3813/4885ALDH1A1 1397/4885HSD17B10 1842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.